

# Placental Pathology, a Survival Guide

Drucilla J. Roberts, MD

● **Placental pathology continues to be an underutilized, undertaught, and inadequately handled surgical subspecialty. The requests for placental pathology are soaring, due partly to demands from obstetricians and to the litigious environment in which they practice, and to improved obstetrical care leading to pregnancies in medically challenging situations. Evaluation of the placenta requires a good understanding of the questions and issues concerning both the fetus/infant and the mother. Information from placental pathology can be critical in early neonatal care and in reproductive planning for the family, and it can provide risk assessment for neurologic outcome of the infant. A comfortable interaction among the obstetric staff, mothers, and pathologists often obviates need for legal intervention in unexpected pregnancy outcomes. Some critical pathologic features that involve maternal and fetal management are illustrated herein. A template for gross examination and a few critical histopathologic diagnostic features with clinicopathologic correlation are included.**

(*Arch Pathol Lab Med.* 2008;132:641–651)

## GROSS PLACENTAL FINDINGS/EXAMINATION

I believe that all placentas should have at least a gross examination, saving the full histopathologic examination for a defined subset (Table 1). At the Massachusetts General Hospital, all placentas are delivered to the pathology department with a minimal required set of clinical information: maternal gravidity, parity, gestational age, and a blank section to provide any other information deemed pertinent by the obstetric staff. Using only these provided data, we triage the placenta into a “hold” or “examine” category. Hold placentas are those that do not meet criteria as described in Table 1 and are basically normal-term singleton livebirths who received prenatal care and delivered in the hospital without maternal or fetal/infant pathologic history or complications. The hold placentas are placed in a large, locked refrigerator for at least 7 days and are disposed of after 7 days so long as the infant is not transferred to the neonatal intensive care unit and the

mother is not readmitted with an obstetric or other complication. Maternal admission and neonatal intensive care unit admission lists are checked daily for these events. The examine category includes all placentas from deliveries other than those described in Table 1 or are maternal readmissions or neonatal intensive care unit admissions.

Placentas are stereotypic organs that lend themselves to template gross description (Table 2), ensuring that all the important information is obtained and facilitating dictation and transcription. Deviations from this template—for example, twin gestation or other multiples or fragmented placentas—can be handled without the template or with minor deviations from it. The template ensures that the most critical information is noted: color, cord length<sup>1–3</sup> (standards in Figure 1), lesions, and trimmed weight.<sup>1,3–7</sup> The importance of these gross findings is listed in Table 3. This also allows for easy sampling, as once the gross template is complete the necessary sections needed for histology are neatly outlined. We take at least 2 sections of cord (proximal to the placenta and proximal to fetus), 1 membrane roll (including the membrane rupture site), and 3 full thickness sections of parenchyma, including chorionic plate vessels. All parenchymal lesions should be sampled (just a small representative section), and at least one “normal” representative section of parenchyma needs to be sampled.

These “chunks” of placenta, the membrane roll, and the cord sections are placed into a small specimen jar with 10% formalin and fixed for at least 4 hours. Very sick babies or mothers need pathologic interpretation promptly, and these specimens should be processed the same day as accessioned. Others can be fixed overnight, or as convenient. We fix the remaining placental tissues as well and save it until the case is complete.

## HISTOLOGIC FINDINGS

Remembering that the placenta is an organ with circulations from both the mother and the fetus, examination of the placenta should look for pathology from both individuals. Historically, the focus of placental histopathology has been on maternal side diseases/disorders. Recently, much attention has been focused on the fetal side. There may be much more importance in the fetal histopathology of the placenta in terms of predicting or explaining subsequent morbidity.

Maternal side diseases/disorders that affect the placenta are many and are too numerous to describe herein. Instead, I will focus on those that have been shown to have important fetal sequelae or recurrence risk.

---

Accepted for publication November 20, 2007.

From the Department of Pathology, Massachusetts General Hospital, Boston.

The author has no relevant financial interest in the products or companies described in this article.

Presented in part at the 28th Annual Course, Current Concepts in Surgical Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, November 2006.


Reprints: Drucilla J. Roberts, MD, Department of Pathology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02115 (e-mail: djroberts@partners.org).

**Table 1. Indications for Placental Examination****Pediatric**

Prematurity/postdates  
 Growth indices: intrauterine growth restriction/macrosomia  
 Unexpected adverse outcome  
 Congenital anomalies  
 Suspicion of fetal infection  
 Fetal hydrops  
 Fetal hematologic abnormalities

**Obstetric**

Stillbirth (important site to obtain tissue for culture for karyotype)  
 Poor obstetric history  
 Maternal disease/death  
 Hypertension  
 Maternal infection  
 Oligo/polyhydramnios  
 Excessive bleeding per vagina  
 Abnormal fetal monitoring  
 In utero therapy  
 Maternal toxin exposure  
 Abnormal placenta noted at delivery

**Figure 1.** Umbilical cord length standards. Term cord length 40 to 70 cm (10th–90th percentile).**Maternal Placental Perfusion Pathologies**

The uterine vessels that perfuse the placenta can be damaged due to myriad diseases/disorders and lead to ischemia to the placenta, either regionally or globally. The resultant placental pathology is an infarct (villi collapsed upon each other with empty intervillous space—no maternal blood—and undergoing necrosis from the inside out—in early stages maintaining fetal blood flow). Regional under/absent perfusion results in a focal placental infarct, usually near the margin, and typically in a pyramidal shape with the base along the maternal floor (Figure 2, A). These infarcts are quite common at term or after term and are related to senescence. Preterm placental infarcts are less common. The significance of infarcts has to do with the placental reserve. Infarcts in normal-sized, well-developed placentas, even if large, are usually of no significance. Although placental infarcts are common, multiple infarcts or infarcts that make up more than 5% of the placental mass are considered pathologic and may impact the fetal oxygen/nutrient state. Small placentas or placentas damaged by other pathologies have less reserve, and therefore the fetus is more susceptible to injury due

to any sized placental infarct. Global ischemia to the placenta from diffuse vascular damage has a different pathology. The infarcts tend to be small, multiple, and more “central” in the placental mass (in the “watershed” zone; Figure 2, B). These, in my experience, are much more characteristic of severe, chronic, uteroplacental vascular insufficiency. In addition to infarcts, which are really absent maternal perfusion, there are other findings that correlate with chronic ischemia to the placenta. These have been well described in the literature<sup>8</sup> and include small villi (usually containing only one capillary), large syncytial knots (containing more than 10 nuclei, often larger than the villous), and absence of mid-sized villi, giving the placental histology a look of only large and small villi with abundant open maternal space (Figure 2, C).

In my experience, placental pathology of ischemia differs from that of hypoxemia. Maternal hypoxemia, generally severe and due to cardiopulmonary disease but also seen in high-altitude pregnancies, does not produce the above described changes of ischemia, but rather placentas with a dramatic increase in the amount of villous vessels (chorangiomas,<sup>9–13</sup> usually more than 20 or so vessels in a

**Table 2. Placental Worksheet/Template for Dictation**

The specimen was received freshly labeled with the patient's name and unit number and consists of a singleton placenta.

Cord insertion \_\_\_\_\_ cm from margin (or \_\_\_\_\_ cm in membranes from margin)

Cord length \_\_\_\_\_ cm

No. of vessels \_\_\_\_\_

Cord color: \_\_\_\_\_ (white, green, yellow, brown)

No. of cord twists in 6 cm = \_\_\_\_\_

Other cord findings \_\_\_\_\_ (knots, nodules, masses, etc)

Membranes inserted \_\_\_\_\_% (marginally, circummarginately, circumvallate)

Membrane rupture site \_\_\_\_\_ cm to margin

Membrane color \_\_\_\_\_

Other membrane findings \_\_\_\_\_ (nodules, hemorrhage, membranous vessels, etc)

The trimmed placental weight is \_\_\_\_\_ g

Disk measurement \_\_\_\_\_ cm in greatest diameter × \_\_\_\_\_ cm thick

Fetal surface findings \_\_\_\_\_ (nodules, masses, chorionic vascular thromboses, etc)

Maternal surface \_\_\_\_\_ (disrupted, masses, calcification, fibrin, hematomas, indentations, etc)

Parenchyma \_\_\_\_\_ (normal = beefy, spongy, red; lesions = number, size, % of mass involved, location)

Summary:

Cassettes:

villous; Figure 3, A) and the presence of easily identifiable erythrocyte precursors (normoblasts; Figure 3, B). I have also seen this in a lethal case of peripartum cardiomyopathy.

Other findings related to maternal-side vascular pathology include thrombophilias.<sup>14</sup> Inherited (eg, protein C or S deficiency, factor V Leiden, sickle cell disease) or acquired maternal thrombophilias (eg, antiphospholipid antibody, and see herein) can lead to markedly increased fibrin/fibrinoid deposition in the maternal or intervillous space (Figure 4, A). The result is the villi are trapped by the material and are “choked,” leading to necrosis. There are some pregnancy-specific disorders leading to increased inter/perivillous fibrin deposition, including maternal floor infarct<sup>15–20</sup> (MFI; Figure 4, B) and massive chronic intervillitis<sup>21–24</sup> (MCI; Figure 4, C). These disorders are idiopathic, have a high recurrence rate in future pregnancies, and are thought to be immune mediated, a sort of maternal host versus fetal allograft rejection reaction.

Maternal floor infarct is a poorly chosen name to a rare finding of a vast amount of the maternal floor effaced by a confluent and thick layer of fibrin/fibrinoid. This layer effectively inhibits maternal perfusion of the associated placenta, which then is perfused only by the “backflow” of adjacent noninvolved regions. MFI is often associated with fetal morbidity and mortality. It is one of the placental causes of an elevated maternal serum  $\alpha$ -fetoprotein. MFI is reported to have a significant recurrence risk; therefore, I recommend reviewing previous obstetric pathologies and alerting the clinicians to the recurrence risk. If there is associated elevated maternal serum  $\alpha$ -fetoprotein as well, this provides a handy tool for the clinicians to follow the next pregnancy.

Massive chronic intervillitis is a striking finding in which the maternal space is filled with CD68-positive histiocytes and an admixed or nodular increase in fibrin is seen. The lesion can occur at any gestational age, although it has been reported to be most common in the first trimester (a cause of chromosomally normal first-trimester abortion). It has reportedly the highest recurrence risk of all placental pathologies and arguably the most significant sequellae, fetal death. The lesion can occur consequentially or be interrupted, without any medical intervention or change in paternity, with totally normal full-term live birth pregnancies. MCI can also be a placental cause of elevated maternal serum  $\alpha$ -fetoprotein. The diagnosis is always most striking in late second or third trimester and can be quite subtle in the first trimester. When diagnosed in a later gestation placenta, all previous obstetric pathology should be reviewed for the possibility of a missed subtle diagnosis.

The fetal consequence of any of these maternal vascular pathologies depends on the reserve of the placenta and fetus but may include intrauterine growth restriction and fetal death in utero.

### Fetal Perfusion Defects

The fetus perfuses the placenta through the umbilical arteries, and the blood flows through the chorionic plate vessels into the villi and returns to the fetus, oxygen and nutrient rich, through the umbilical vein. The villi are perfused internally by the fetus and externally by the mother. Fetal perfusion defects have a characteristic pathology unique from that of maternal vascular pathology. The in-

tervillous space (maternal lakes) are patent, but the villi are empty of functioning vessels and fetal blood (Figure 5, A). The term *fetal thrombotic vasculopathy* (FTV)<sup>25–28</sup> is the generic term used for all fetal perfusion pathologies and includes those that are thromboembolic (eg, from a fetal or umbilical source as might be seen in fetal diffuse intravascular coagulopathy, partial or intermittent cord obstructions as in true umbilical knots or membranous vessels), due to heart failure (leading to fetal-side hypoxia and endothelial damage presenting as sloughed endothelium in the villi and fragmented fetal red blood cells, previously called hemorrhagic endovasculitis [HEV]<sup>29–34</sup>; Figure 5, C), due to damage to any fetal vascular wall (meconium myonecrosis: see below, inflammatory migration through a vessel as associated with acute chorioamnionitis, or inflammatory damage in chronic villitis), or due to hematologic disturbances (as seen in the increased red cell mass in infants of diabetic mothers or in leukemias and leukemoid reactions, as in infants with trisomy 21).

Toxic damage to fetal vessels results from meconium myonecrosis.<sup>35–37</sup> A high concentration of meconium exposure over a prolonged time interval can be toxic to the myocytes of the vessels in the umbilical cord or chorionic plate. The meconium appears to stimulate a chemotaxis and the sequellae of that (as well as an apparently direct toxic effect to the smooth muscle of the vascular wall). The lesion consists of an apoptosis of the smooth muscle cells (Figure 5, B) with a spatial distribution: the closer the myocytes are to the amniotic fluid, the more damaging. This results in a flaccid vessel, which can collapse and interrupt blood flow to both the fetus and/or the placenta, often with disastrous consequences. It is a common finding I see in postdate deliveries of unexpected “bad babies” who later are given the diagnosis of “cerebral palsy.” There are no prospective trials, so currently this finding is diagnosed as “meconium myonecrosis” with a note to the neonatologist/pediatrician and delivering personnel that this infant should be followed earlier and more often to ensure that neurodevelopment is evaluated to assess for delay and intervene if appropriate.

Hemorrhagic endovasculitis is a distinctive histopathologic finding of damage to the endothelium of the villous vessels, resulting in extravasation of the fetal red blood cells into the vessel wall (Figure 5, C).<sup>38–44</sup> Well-developed cases phenocopy recanalization of occluded vessels. Although this finding is thought to be due to “slow flow” or heart failure on the fetal part, it is most commonly seen in stillbirths and is likely a sequellae of fetal death. In livebirths, we consider it an ominous finding, a near-miss stillbirth, and have most often seen it in cases of severe fetal heart failure due to structural anomalies or severe hypoxemia.

Fetal consequence of FTV is a function of the amount of the placental mass involved and the specific etiology leading to FTV. Some have noted that focal FTV generally has no clinical significance, whereas diffuse FTV, especially due to HEV, is associated with grave neurologic compromised, and I often consider these near-miss stillbirths.

When confronted with FTV in a case, I always review the differential diagnosis: look for anatomic, inflammatory, toxic, and neoplastic etiologies to explain the finding, and put that in the report. FTV is often a pathologic finding without an anatomically determined etiology, and should be noted as such.

There are at least 2 other findings that suggest vascular

**Table 3. Gross Findings and Their Significance**

Cord length
Short or flat umbilical cord
Poor fetal activity
Neuromuscular compromise
Oligohydramnios
Associated with limb/body wall complex, gastroschisis
Long or hypertwisted umbilical cord
Increased fetal activity
Polyhydramnios
Heart failure (increased distance to pump)
Increased risk of cord accident
Placental weight
Light placenta (<10th percentile for gestational age)
Chronic uteroplacental insufficiency
Chromosomal anomalies
Maternal tobacco use
Congenital infection
Heavy placenta (>95th percentile for gestational age)
Hydrops placentalis/fetalis
Macrosomia, infant of diabetic mother
Beckwith-Weidemann syndrome
Triploidy
Discolored placenta
Brown—hemosiderin
Green—meconium
Yellow—chorioamnionitis

compromise on the fetal side. These include massive villous edema, which may compress the small villous vessels (Figure 5, D), and intravillous hemorrhage (rupture of the villous vessels and free blood in the villous stroma, a finding seen in acute abruptions or cord accidents; Figure 5, E).

### Placental Findings Associated With Fetal Neurologic Compromise

There are many findings associated with neurocompromise in the neonate, either immediate or delayed, expected or unexpected, in the preterm, term, or postterm infant. They have been nicely reviewed, and those reviews should be read by all with an interest in placental pathology.<sup>45,46</sup> The common findings include vascular compromise. I will review the findings and suggest reporting methods to minimize familial terror and maximize pediatric observance.

Inflammatory cells migrate through the fetal vessels in response to chemoattractants, including infectious organisms and meconium. The umbilical cord (Figure 6, A) and chorionic plate vessels (Figure 6, B) are most often involved. The result is local destruction and/or injury to the endothelium and vascular wall, leading to a thrombogenic focus, loss of vascular patency, and release of cytokines and other factors systemically (to the placenta and fetus). Marked "vasculitis" from fetal sources has been associated with neurologic compromise, likely for these reasons (see below for a more extensive discussion).<sup>47</sup>

Good, controlled data are limited in this critical arena. Most studies are retrospective and uncontrolled. What are best defensible include massive/diffuse acute villous edema associated with cerebral palsy<sup>48,49</sup> and marked chorionic plate vasculitis associated with other forms of neurologic compromise.<sup>35-37,46-50</sup> Some pretty good retrospec-

tive data suggest that FTV from meconium myonecrosis is also associated with severe neurologic delay.<sup>35,51</sup> In my practice, these features are diagnosed with caution and with an appropriate phone call or comment in the report. I also try to get the report to both the delivering clinician as well as to the neonatologist and/or pediatrician (to ensure that the infant is followed). I use the following note when I am most concerned about the findings (and I always call the clinicians):


Comment: These findings are diffuse and dramatic. In some studies, similar findings have been associated with sequellae (neurodevelopmental delay, seizures, etc).

### Placental Pathologic Findings With Immediate Neonatal Care Implications

The fetal implications of placental examination involve the findings that: require immediate clinical intervention, suggest a newborn risk for disease, explain an in utero etiology of immediate neonatal compromise or fetal/neonatal death, time an insult in broad time windows (more important in legal questions), and may have implications in assigning risk for the development of adult chronic disease.

Immediately relevant diagnoses are rare in placental pathology but are significant. Anything hematogenously disseminated by a mother or fetus can be identified by placental histopathologic examination. These include infectious organisms delivered to the placenta during maternal sepsis or viremia, thromboemboli, and metastatic disease from maternal<sup>52</sup> or fetal sources.<sup>53,54</sup> The cellular makeup of the blood from a mother or baby can also show evidence of maternal disease (eg, sickle cell disease or trait) or fetal disease (eg, dyserythropoetic anemia,<sup>55</sup>  $\alpha$ -thalassemia,<sup>56</sup> etc). Suggestions of fetal maldevelopment can be made based on placental pathologic findings (single umbilical artery and urinary tract anomalies, for example<sup>57</sup>). And some specific classes of diseases may first present in the placenta, particularly inborn errors of metabolism.<sup>58,59</sup>

Congenital infections include most commonly those "ascending" from cervicovaginal flora causing acute chorioamnionitis or, more rarely, "transplacental" from hematogenously spread maternal disease.<sup>60,61</sup> Acute chorioamnionitis (ACA; Figure 7, A) is a very common histopathologic finding of a neutrophilic infiltrate in the placental membranes.<sup>60,61</sup> It is considered to be nearly always due to a microbial infection of the amniotic fluid. There are some specific single-organism infectious etiologies of ACA that are diagnosable from placental histopathology (Table 4). The sequellae of ACA includes preterm rupture of membranes, preterm delivery, and thus all the sequellae of prematurity. The less commonly associated fetal sepsis is difficult to predict<sup>62</sup>; the only histopathologic finding associated with fetal sepsis is the presence of umbilical cord "arteritis" (fetal exudate through the umbilical arteries into Wharton jelly). Although the significance of diagnosing ACA and umbilical arteritis is not to be understated, the more serious finding related to ACA is the local vascular damage and systemic endothelial damage from fetal inflammatory cells.<sup>47,63-65</sup> Local damage to the fetal vessels in the placenta results in a thrombogenic focus and/or an incompetent vessel, as discussed above. Thrombi can form in these damaged vessels and remain attached to the vessel or can embolize downstream to the villi (resulting in a fetal side placental infarct) or via the umbilical vein back to the fetus, where the most likely sites of em-



**Figure 2.** A, A placental infarct from maternal nonperfusion. Notice wedge shape and broad base along maternal floor. B, Photomicrograph showing global ischemia results in roundish central infarct, as seen in maternal hypertensive disorders. C, Hypermaturation villi, small, large knots, one or so capillaries per villous, and abundant open space between villi (hematoxylin-eosin, original magnifications  $\times 4$  [A and B] and  $\times 10$  [C]).


**Figure 3.** A, Photomicrograph showing chorangiomas: more than 10 capillaries per villous, often more than 20. B, Photomicrograph demonstrating presence of nucleated red blood cells (hematoxylin-eosin, original magnifications  $\times 10$  [A] and  $\times 40$  [B]).

**Figure 4.** A, Photomicrograph showing increased perivillous fibrin with some live (vascular) and some dead (avascular) villi. B, Maternal floor infarct with band of fibrin more than 4 villi deep along the maternal floor. C, Massive chronic intervillitis showing abundant maternal histiocytes in the intervillous space with fibrin (along left side of image) (hematoxylin-eosin, original magnifications  $\times 10$  [A],  $\times 4$  [B], and  $\times 20$  [C]).

bolization will be cerebral or renal. The effects would be obvious: congenital embolic stroke or renal or other visceral infarcts. The placenta should always be examined as a source for thromboemboli in neonatally diagnosed visceral infarcts or embolic strokes. Other than causing a thrombogenic site, the fetal inflammatory infiltrate is very slow to chemotax, resulting in slow movement out of the vessel, stasis within the vessel wall and lumen, and premature release of cytoplasmic contents (lysozymes and cytokines), which exacerbate the local response and stimulate the systemic response. This can result in a fetal septiclike picture without true sepsis.

The other route of congenital infection is through the


placenta from a maternal hematogenous source.<sup>66,67</sup> Although the placenta, via its trophoblastic barrier, provides a protective function from transmission of infectious organisms and toxins, it also is the permissive source of transplacental transfer of these as well. Many viral particles passively transfer across the trophoblastic barrier, and others are actively transported. All infectious placentitis are rare. The most common transplacental infection is cytomegalovirus (CMV),<sup>67</sup> which can cause congenital infection either from primary or recurrent disease,<sup>67</sup> with others including parvovirus, herpes simplex virus, hepatitis B and C, and treponema pallidum. In active infections, many placentas will have characteristic histopathology,



**Figure 5.** A, Avascular villi (arrows), from no fetal perfusion, open maternal space. Some villi are not affected and have normal vasculature (arrowheads). B, Meconium myonecrosis of an umbilical artery. Arrows highlight meconium in macrophages. Arrowheads designate apoptotic myocytes. C, Hemorrhagic endovasculitis with arrows showing vessels with a “recanalization” look due to necrosis of the endothelium. D, Massive acute villous edema and chorangiosis. E, Intravillous hemorrhage (arrows) in a documented acute abruption (hematoxylin-eosin, original magnifications  $\times 10$  [A, C, and D] and  $\times 20$  [B and E]).

but often the findings are subtle (as in parvovirus, where inclusion is only present in fetal red blood cells) or absent (hepatitis B and C). The classic lesion is chronic villitis (Figure 7, B), a maternal inflammation of the villous stroma, often with associated intervillitis.<sup>68</sup> Damage from chronic villitis is due to both the rare congenital infection

as well as the stromal reaction/inflammation, which results in vascular compression, villous ischemia, and necrosis (avascular villi). Most chronic villitides are not infectious in etiology (only about 1% are) and are thought to be a maternal immune-regulated rejection of the fetal allograft (see below).<sup>69,70</sup>



**Figure 6.** A, Umbilical “phlebitis”: fetal white blood cells marginating through umbilical vein muscle. B, Chorionic plate vessel with chorionic vasculitis with margination of fetal inflammatory cells (hematoxylin-eosin, original magnifications  $\times 40$  [A] and  $\times 4$  [B]).

**Figure 7.** A, Photomicrograph of acute chorioamnionitis. B, Photomicrograph showing chronic villitis (hematoxylin-eosin, original magnifications  $\times 4$  [A] and  $\times 20$  [B]).

**Figure 8.** A, A placenta with a fetus later diagnosed with GM1 gangliosidosis with arrows highlighting vacuolated stroma of villous trophoblast. B, Photomicrograph showing mesenchymal dysplasia in a case later documented to be an infant with Beckwith-Wiedemann syndrome. Notice normal-appearing villi admixed with large villous with well-demarcated cistern and peripheralized large vessels (hematoxylin-eosin, original magnifications  $\times 20$  [A] and  $\times 4$  [B]).

**Table 4. Acute Chorioamnionitis With Specific Infectious Etiologies Identifiable on Hematoxylin-Eosin**

Group B streptococcus
Can present without rupture of membranes or chorioamnionitis
Rarely associated with acute villitis
Organisms can be present in villous vessels or on amnion, easily identified on hematoxylin-eosin
Often presents with necrotizing acute chorioamnionitis with intact amnion
Fusobacteria
Necrotizing acute chorioamnionitis with a blurring necrosis of amnion
Filamentous organisms can be seen on hematoxylin-eosin on amniotic surface
<i>Listeria monocytogenes</i>
Micro and macro placental abscesses
Acute villitis with acute chorioamnionitis
Forms present on silver stain
<i>Candida albicans</i>
Peripheral abscesses (surface) on the umbilical cord (can be seen grossly)
Hyphae and cyst forms identifiable in abscesses

Specific diseases that allow for survival of the fetus can often be diagnosed first by placental pathology. Most in-born errors of metabolism will present as foamy distention of the syncytial trophoblastic cytoplasm, a diagnosis that ensures rapid specific diagnosis and early intervention as well as family reproductive counseling (Figure 8, A).<sup>58</sup> Beckwith-Weidemann syndrome, a genetic disease characterized by increased incidence of pediatric tumors as well as other findings, can be suspected based on placental examination, as they characteristically have placentomegaly with mesenchymal dysplasia (Figure 8, B).<sup>71-74</sup>

Placental metastases from fetal neoplasms are rare. Neuroblastoma, the most common solid malignant tumor of childhood, is the most common fetal malignancy that involves the placenta,<sup>54,75</sup> followed by hepatoblastoma<sup>76,77</sup> and leukemia.<sup>78</sup> Not infrequently, the fetus shows hydrops fetalis, and for that reason congenital malignancies should be added to the list of differential diagnoses of nonimmunologic hydrops fetalis. On gross examination, these tumors are frequently associated with an enlarged placenta (usually >1000 g) that is edematous and pale without visible nodules and resembles the gross appearance of erythroblastosis fetalis. On microscopic examination, the malignant tumor cells are frequently confined to the fetal circulation and rarely extend to the parenchyma of the chorionic villi in cases of neuroblastoma and hepatoblastoma; however, in cases of placental involvement by leukemia, there is typically diffuse infiltration of the chorionic villi by malignant fetal cells. This histologic finding is frequently associated with prominent hydropic change of the chorionic villi. Fetal primitive malignant tumors involving the placenta may be confused with intravascular hematopoiesis. Of note, this entity is not associated with an enlarged placenta, and it is typically seen in chorionic villi in abortions obtained from the 5 to 11 weeks' gestation.<sup>79</sup> Finally, in contrast to maternal metastases, there are only very rare maternal consequences related to fetal malignancies.<sup>80</sup>

## Placental Pathology With Maternal Care Implications

Placental pathology can offer information regarding maternal health and the risk for future pregnancy complications. Much interest in the maternal side of the placenta has related to the effects of maternal disease on placental function. For example, the effects of hypertensive diseases (whether pregnancy related or not) on placental function and pathology have been discussed above. We can use these findings in nonhypertensive pregnancies to suggest ischemia related to other etiologies, that is, tobacco use, maternal sickle cell disease or trait, uterine anomalies like bicornuate uterus, etc.

Maternal infectious diseases are usually diagnosed before the placental pathology report returns, but some cases, especially congenital CMV, suggest further maternal testing. Congenital CMV severe enough to result in neonatal disease or intrauterine fetal death (IUFD) is rare and related to viral load. In most cases, the infection is the first for the mother, resulting in high viral load and transfer to the fetus through the placenta, resulting in fetal death. In other cases, recurrent CMV or CMV placentitis presenting in an older mother and resulting in fetal mortality may be enough to suspect maternal immunodeficiency and is an indication to evaluate for maternal HIV status.<sup>81</sup>

Syphilis<sup>82</sup> and herpes simplex virus (genital or oral)<sup>83-85</sup> often are clinically silent in pregnancy and evidenced only postpartum with neonatal sepsis or IUFD. Most other infections will present antenatal with some maternal symptoms.

Maternal malignant diseases can metastasize to the placenta or originate in the placenta, and they certainly carry significant maternal risk. Although the most common malignancies that present during pregnancy include those common in the reproductive age, metastases are typically hematogenous and occur early during pregnancy. Melanoma represents 8% of cancers in pregnancy, but it accounts for 31% of all placental metastases.<sup>86</sup> Leukemia and lymphoma (15%), followed by breast (13%) and lung (11%) carcinomas, sarcomas (8%), gastric carcinoma (3%), and gynecologic cancers (3%) are the other most common maternal malignancies that have been reported to involve the placenta.<sup>52,87-94</sup> On gross examination, the placenta may be enlarged or the lesions may be noted as dark brown areas simulating an infarction in up to 50% of cases.<sup>95,96</sup> On microscopic examination, the neoplastic infiltrate typically occupies the intervillous space, a component of the maternal vascular system, but in some instances villous or even fetal vascular invasion may be present, although extremely rare. The extent of placental involvement does not correlate with the incidence of fetal metastases, and in most instances there is placental metastases without fetal involvement<sup>89,97</sup>; however, the finding of fetal involvement is almost lethal for the fetus or newborn. It is also important to remember that there are primary lesions of the placenta that may be confused with metastatic deposits of maternal origin. These include placental melanocytic deposits seen in babies with congenital melanocytic nevi that can be confused with metastatic melanoma,<sup>98,99</sup> and adrenocortical or hepatic nodules that may occur within the placental tissue and may mimic more commonly metastatic carcinoma.<sup>100-102</sup> Finally, maternal malignant tumor metastatic to the placenta is indicative of stage IV disease for the mother and carries a very poor prognosis. As a

**Table 5. Placental Findings and Their Relative Timing to Delivery**

Findings associated with chronic in utero compromise (>48 h, usually weeks)
Placental weight <10th or >99th percentile for gestational age trimmed
Short or long umbilical cord (expect 40–70 cm at term)
Hypertwisted or hypotwisted umbilical cord (normally 1 twist per 3 cm)
Amnion nodosom
Multiple or large placental infarcts (>5% of placental mass)
Decidual vasculopathy
Chronic abruption
Maternal floor infarction
Necrotizing funisitis
Chronic villitis
Fetal thrombotic vasculopathy
Findings associated with acute in utero compromise (<18 h)
Normal placental weight
Acute villous edema
Intravillous hemorrhage
Acute abruption
Meconium not involving umbilical cord (if <40 wk)
Findings associated with subacute in utero compromise (18–48 h)
Chorangiosis
Normoblastemia
Necrotizing acute chorioamnionitis
Meconium in umbilical cord and/or meconium myonecrosis

rule, it is recommended to examine all placentas in cases in which a malignancy is known in the mother.

There are findings that may lead to clinical intervention or counseling in or before future pregnancies. These are the findings that are believed to be due to an abnormal immune response maternally “rejecting” the placental/fetal allograft. Although the specific etiology of these placental findings is unknown, their well-documented recurrence risk suggests they are immune based. The diagnoses probably represent a single class of disorders that have been subdivided pathologically and include those discussed above: maternal floor infarct,<sup>16–18,20,103,104</sup> villitis of unclear etiology,<sup>105</sup> massive chronic intervillitis/massive intervillous fibrin deposition.<sup>21–24,106</sup> The recurrence risk varies from 33% to 80% but is just an estimate, as no good denominator exists for the cases. Although no specific therapy is accepted for these cases, clinical intervention has included antithrombotic therapy, systemic steroids, as well as counseling about alternatives for reproduction.

#### Placental Findings With Legal Implications

We live in a litigious society with unreasonable expectations for pregnancy outcome. The unexpected “bad” outcome is filled with anger and guilt from the family and from the clinician. The pathologist can offer the best intervention, with a clearly presented, unbiased report that can offer insight into the timing of the insult, most often clearing the clinician from liability and helping the family with understanding and grieving. In cases of unexpected complications associated with a livebirth, placental examination is critical. Timely interpretation and, hopefully, meeting with the family, neonatologist, obstetricians or other delivering personnel, nurses, and others involved in the care can be instrumental in obviating the need for legal interference. I truly believe that this is a duty of the pathologist at least to offer to have these meetings. The

same holds for the unexpected stillbirth, in which, hopefully, the placental and autopsy findings can be discussed.

Most litigious claims deal with a critical period where intervention, if obtained, would have led to a “normal” outcome. In my practice, both in hospital and legal expert witness cases, the in-labor catastrophes are rare and, when present, are rarely either diagnosable or intervenable by the clinicians. Most cases of unexpected bad outcomes have chronic insults to the placenta. Most of the findings have been described above. The findings and their relative timings in relationship to delivery are presented in Table 5.

#### SUMMARY AND CONCLUSIONS

The placenta is a valuable tool to understand in utero events, predict neonatal outcome, help with reproductive choices, and prevent frivolous lawsuits. Placental pathologists are useful consultants to both obstetric and pediatric practices. Examination of the placenta is indicated in a defined subset of all deliveries.

#### References

1. Wigglesworth JS, Singer DB. *Textbook of Fetal and Perinatal Pathology*. Vol 1. 5th ed. London, United Kingdom: Blackwell Science; 1998:1205.
2. Mills JL, Harley EE, Moessinger AC. Standards for measuring umbilical cord length. *Placenta*. 1983;4:423–426.
3. Benirschke K, Kaufman P, Baergen RN. *The Pathology of the Human Placenta*. 5th ed. New York, NY: Springer-Verlag; 2006:1050.
4. Hecht JL, Kliman HJ, Allred EN, et al. Reference weights for placentas delivered before the 28th week of gestation. *Placenta*. 2007;28:987–990.
5. Lee Y, Kim KR, McKeon F, et al. A unifying concept of trophoblastic differentiation and malignancy defined by biomarker expression. *Hum Pathol*. 2007;38:1003–1013.
6. Pinar H, Stephens M, Singer DB, et al. Triplet placentas: reference values for weights. *Pediatr Dev Pathol*. 2002;5:495–498.
7. Pinar H, Sung CJ, Oyer CE, Singer DB. Reference values for singleton and twin placental weights. *Pediatr Pathol Lab Med*. 1996;16:901–907.
8. Redline RW, Boyd T, Campbell V, et al. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. *Pediatr Dev Pathol*. 2004;7:237–249.
9. Ogino S, Redline RW. Villous capillary lesions of the placenta: distinctions between chorangioma, chorangiomatosis, and chorangiosis. *Hum Pathol*. 2000;31:945–954.
10. Caldarella A, Buccoliero AM, Taddei GL. Chorangiosis: report of three cases and review of the literature. *Pathol Res Pract*. 2003;199:847–850.
11. Schwartz DA. Chorangiosis and its precursors: underdiagnosed placental indicators of chronic fetal hypoxia. *Obstet Gynecol Surv*. 2001;56:523–525.
12. De La Ossa MM, Cabello-Inchausti B, Robinson MJ. Placental chorangiosis. *Arch Pathol Lab Med*. 2001;125:1258.
13. Altshuler G. Chorangiosis. An important placental sign of neonatal morbidity and mortality. *Arch Pathol Lab Med*. 1984;108:71–74.
14. Raspolini MR, Oliva E, Roberts DJ. Placental histopathologic features in patients with thrombophilic mutations. *J Matern Fetal Neonatal Med*. 2007;20:113–123.
15. Mandsager NT, Bendon R, Mostello D, Rosenn B, Miodovnik M, Siddiqi TA. Maternal floor infarction of the placenta: prenatal diagnosis and clinical significance. *Obstet Gynecol*. 1994;83:750–754.
16. Nickel RE. Maternal floor infarction: an unusual cause of intrauterine growth retardation. *Am J Dis Child*. 1988;142:1270–1271.
17. Katz VL, Bowes WA Jr, Sierkh AE. Maternal floor infarction of the placenta associated with elevated second trimester serum alpha-fetoprotein. *Am J Perinatol*. 1987;4:225–228.
18. Naeye RL. Maternal floor infarction. *Hum Pathol*. 1985;16:823–828.
19. Clewell WH, Manchester DK. Recurrent maternal floor infarction: a preventable cause of fetal death. *Am J Obstet Gynecol*. 1983;147:346–347.
20. Katzman PJ, Genest DR. Maternal floor infarction and massive perivillous fibrin deposition: histological definitions, association with intrauterine fetal growth restriction, and risk of recurrence. *Pediatr Dev Pathol*. 2002;5:159–164.
21. Doss BJ, Greene MF, Hill J, Hefner LJ, Bieber FR, Genest DR. Massive chronic intervillitis associated with recurrent abortions. *Hum Pathol*. 1995;26:1245–1251.
22. Labarrere C, Mullen E. Fibrinoid and trophoblastic necrosis with massive chronic intervillitis: an extreme variant of villitis of unknown etiology. *Am J Reprod Immunol Microbiol*. 1987;15:85–91.
23. Bane AL, Gillan JE. Massive perivillous fibrinoid causing recurrent placental failure. *BJOG*. 2003;110:292–295.
24. Weber MA, Nikkels PG, Hamoen K, Duvekot JJ, de Krijger RR. Co-occurrence of massive perivillous fibrin deposition and chronic intervillitis: case report. *Pediatr Dev Pathol*. 2006;9:234–238.

25. Redline RW, Pappin A. Fetal thrombotic vasculopathy: the clinical significance of extensive avascular villi. *Hum Pathol.* 1995;26:80–85.
26. Kraus FT, Acheen VI. Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. *Hum Pathol.* 1999;30:759–769.
27. Kraus FT. Placenta: thrombosis of fetal stem vessels with fetal thrombotic vasculopathy and chronic villitis. *Pediatr Pathol Lab Med.* 1996;16:143–148.
28. Redline RW, Ariel I, Baergen RN, et al. Fetal vascular obstructive lesions: nosology and reproducibility of placental reaction patterns. *Pediatr Dev Pathol.* 2004;7:443–452.
29. Sander CM. Update: etiology, diagnosis and management of hemorrhagic endovasculitis of the placenta. *Compr Ther.* 1991;17:16–19.
30. Rayburn W, Sander C, Barr M Jr, Rygiel R. The stillborn fetus: placental histologic examination in determining a cause. *Obstet Gynecol.* 1985;65:637–641.
31. Sander CH, Kinnane L, Stevens NG. Hemorrhagic endovasculitis of the placenta: a clinicopathologic entity associated with adverse pregnancy outcome. *Compr Ther.* 1985;11:66–74.
32. Stevens NG, Sander CH. Placental hemorrhagic endovasculitis: risk factors and impact on pregnancy outcome. *Int J Gynaecol Obstet.* 1984;22:393–397.
33. Sander CH, Stevens NG. Hemorrhagic endovasculitis of the placenta: an in-depth morphologic appraisal with initial clinical and epidemiologic observations. *Pathol Annu.* 1984;19(pt 1):37–79.
34. Sander CH. Hemorrhagic endovasculitis and hemorrhagic villitis of the placenta. *Arch Pathol Lab Med.* 1980;104:371–373.
35. Altschuler G, Arizawa M, Molnar-Nadasdy G. Meconium-induced umbilical cord vascular necrosis and ulceration: a potential link between the placenta and poor pregnancy outcome. *Obstet Gynecol.* 1992;79:760–766.
36. Altschuler G, Hyde S. Meconium-induced vasoconstriction: a potential cause of cerebral and other fetal hypoperfusion and of poor pregnancy outcome. *J Child Neurol.* 1989;4:137–142.
37. King EL, Redline RW, Smith SD, Kraus FT, Sadovsky Y, Nelson DM. Myocytes of chorionic vessels from placentas with meconium-associated vascular necrosis exhibit apoptotic markers. *Hum Pathol.* 2004;35:412–417.
38. Sander CM, Gilliland D, Richardson A, Foley KM, Fredericks J. Stillbirths with placental hemorrhagic endovasculitis: a morphologic assessment with clinical implications. *Arch Pathol Lab Med.* 2005;129:632–638.
39. Sander CM, Gilliland D, Akers C, McGrath A, Bismar TA, Swart-Hills LA. Livebirths with placental hemorrhagic endovasculitis: interlesional relationships and perinatal outcomes. *Arch Pathol Lab Med.* 2002;126:157–164.
40. Salafia CM, Pezzullo JC, Miniur VK, Divon MY. Placental pathology of absent and reversed end-diastolic flow in growth-restricted fetuses. *Obstet Gynecol.* 1997;90:830–836.
41. Sander CM, Gilliland D, Flynn MA, Swart-Hills LA. Risk factors for recurrence of hemorrhagic endovasculitis of the placenta. *Obstet Gynecol.* 1997;89:569–576.
42. Sander CM. Hemorrhagic endovasculitis of the placenta. *Am J Obstet Gynecol.* 1992;167:1483.
43. Owen J. Hemorrhagic endovasculitis of the placenta and fetomaternal hemorrhage: a relationship? *Am J Obstet Gynecol.* 1992;167:860–861.
44. Salafia CM, Vintzileos AM, Silberman L, Bantham KF, Vogel CA. Placental pathology of idiopathic intrauterine growth retardation at term. *Am J Perinatol.* 1992;9:179–184.
45. Beaudet L, Karuri S, Lau J, Magee F, Lee SK, von Dadelszen P. Placental pathology and clinical outcomes in a cohort of infants admitted to a neonatal intensive care unit. *J Obstet Gynaecol Can.* 2007;29:315–323.
46. Redline RW. Placental pathology and cerebral palsy. *Clin Perinatol.* 2006;33:503–516.
47. Redline RW. Infections and other inflammatory conditions. *Semin Diagn Pathol.* 2007;24:5–13.
48. Redline RW, Wilson-Costello D, Borawski E, Fanaroff AA, Hack M. Placental lesions associated with neurologic impairment and cerebral palsy in very low-birth-weight infants. *Arch Pathol Lab Med.* 1998;122:1091–1098.
49. Redline RW, Wilson-Costello D, Borawski E, Fanaroff AA, Hack M. The relationship between placental and other perinatal risk factors for neurologic impairment in very low birth weight children. *Pediatr Res.* 2000;47:721–726.
50. Redline RW. Inflammatory responses in the placenta and umbilical cord. *Semin Fetal Neonatal Med.* 2006;11:296–301.
51. Redline RW. Severe fetal placental vascular lesions in term infants with neurologic impairment. *Am J Obstet Gynecol.* 2005;192:452–457.
52. Altman JF, Lowe L, Redman B, et al. Placental metastasis of maternal melanoma. *J Am Acad Dermatol.* 2003;49:1150–1154.
53. Rivasi F, Gasser B, Collina G, Massolo F, Philippe E. Congenital fetal neuroblastoma. *Ann Pathol.* 2001;21:76–80.
54. Perkins DG, Kopp CM, Haust MD. Placental infiltration in congenital neuroblastoma: a case study with ultrastructure. *Histopathology.* 1980;4:383–389.
55. Roberts DJ, Nadel A, Lage J, Rutherford CJ. An unusual variant of congenital dyserythropoietic anaemia with mild maternal and lethal fetal disease. *Br J Haematol.* 1993;84:549–551.
56. Suh YK. Placental pathology casebook: alpha-thalassemia: differential diagnosis. *J Perinatol.* 1994;14:319–321.
57. Prucka S, Clemens M, Craven C, McPherson E. Single umbilical artery: what does it mean for the fetus? A case-control analysis of pathologically ascertained cases. *Genet Med.* 2004;6:54–57.
58. Roberts DJ, Ampola MG, Lage JM. Diagnosis of unsuspected fetal metabolic storage disease by routine placental examination. *Pediatr Pathol.* 1991;11:647–656.
59. Case Records of the Massachusetts General Hospital: weekly clinicopathological exercises. Case 23-1997—a premature newborn infant with congenital ascites. *N Engl J Med.* 1997;337:260–267.
60. Redline RW, Faye-Petersen O, Heller D, Qureshi F, Savell V, Vogler C. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. *Pediatr Dev Pathol.* 2003;6:435–448.
61. Redline RW. Placental inflammation. *Semin Neonatal.* 2004;9:265–274.
62. de Araujo MC, Schultz R, Vaz FA, Massad E, Feferbaum R, Ramos JL. A case-control study of histological chorioamnionitis and neonatal infection. *Early Hum Dev.* 1994;40:51–58.
63. Holcroft CJ, Askin FB, Patra A, Allen MC, Blakemore KJ, Graham EM. Are histopathologic chorioamnionitis and funisitis associated with metabolic acidosis in the preterm fetus? *Am J Obstet Gynecol.* 2004;191:2010–2015.
64. Pacora P, Chaiworapongsa T, Maymon E, et al. Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. *J Matern Fetal Neonatal Med.* 2002;11:18–25.
65. Yoon BH, Romero R, Park JS, et al. The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. *Am J Obstet Gynecol.* 2000;183:1124–1129.
66. Altschuler G, Russell P. The human placental villitides: a review of chronic intrauterine infection. *Curr Top Pathol.* 1975;60:64–112.
67. Pusztai R, Lukacs A, Kovacs I. Mother-to-fetus transmission of cytomegalovirus: a review. *Acta Microbiol Immunol Hung.* 2004;51:385–401.
68. Gersell DJ. Chronic villitis, chronic chorioamnionitis, and maternal floor infarction. *Semin Diagn Pathol.* 1993;10:251–266.
69. Redline RW, Abramowsky CR. Clinical and pathologic aspects of recurrent placental villitis. *Hum Pathol.* 1985;16:727–731.
70. Redline RW, Patterson P. Villitis of unknown etiology is associated with major infiltration of fetal tissue by maternal inflammatory cells. *Am J Pathol.* 1993;143:473–479.
71. Chan YF, Sampson A. Placental mesenchymal dysplasia: a report of four cases with differentiation from partial hydatidiform mole. *Aust N Z J Obstet Gynaecol.* 2003;43:475–479.
72. Matsui H, Iitsuka Y, Yamazawa K, et al. Placental mesenchymal dysplasia initially diagnosed as partial mole. *Pathol Int.* 2003;53:810–813.
73. Khong TY. Placental vascular development and neonatal outcome. *Semin Neonatal.* 2004;9:255–263.
74. Gibson BR, Muir-Padilla J, Champeaux A, Suarez ES. Mesenchymal dysplasia of the placenta. *Placenta.* 2004;25:671–672.
75. Ohyama M, Itani Y, Yamanaka M, et al. Maternal, neonatal, and placental features associated with diffuse chorioamnionic hemosiderosis, with special reference to neonatal morbidity and mortality. *Pediatrics.* 2004;113:800–805.
76. Robinson HB Jr, Bolande RP. Case 3: fetal hepatoblastoma with placental metastases. *Pediatr Pathol.* 1985;4:163–167.
77. Doss BJ, Vicari J, Jacques SM, Qureshi F. Placental involvement in congenital hepatoblastoma. *Pediatr Dev Pathol.* 1998;1:538–542.
78. Las Heras J, Leal G, Haust MD. Congenital leukemia with placental involvement: report of a case with ultrastructural study. *Cancer.* 1986;58:2278–2281.
79. Alenghat E, Esterly JR. Intravascular hematopoiesis in chorionic villi. *Am J Clin Pathol.* 1983;79:225–227.
80. Allen AT, Dress AF, Moore WF. Mirror syndrome resulting from metastatic congenital neuroblastoma. *Int J Gynecol Pathol.* 2007;26:310–312.
81. Schwabke K, Henry K, Balfour HH Jr, Olson D, Crane RT, Jordan MC. Congenital cytomegalovirus infection as a result of nonprimary cytomegalovirus disease in a mother with acquired immunodeficiency syndrome. *J Pediatr.* 1995;126:293–295.
82. Genest DR, Choi-Hong SR, Tate JE, Qureshi F, Jacques SM, Crum C. Diagnosis of congenital syphilis from placental examination: comparison of histopathology, Steiner stain, and polymerase chain reaction for *Treponema pallidum* DNA. *Hum Pathol.* 1996;27:366–372.
83. Yorty JL, Bonneau RH. Transplacental transfer and subsequent neonate utilization of herpes simplex virus-specific immunity are resilient to acute maternal stress. *J Virol.* 2003;77:6613–6619.
84. Satoras A, Ramirez NC, Bartholomew D, Davis J, Nuovo GJ. Histologic correlates of viral and bacterial infection of the placenta associated with severe morbidity and mortality in the newborn. *Hum Pathol.* 2004;35:536–545.
85. Chatterjee A, Chartrand SA, Harrison CJ, Fely-Duckworth A, Bewtra C. Severe intrauterine herpes simplex disease with placentitis in a newborn of a mother with recurrent genital infection at delivery. *J Perinatol.* 2001;21:559–564.
86. Dildy GA III, Moise KJ Jr, Carpenter RJ Jr, Klima T. Maternal malignancy metastatic to the products of conception: a review. *Obstet Gynecol Surv.* 1989;44:535–540.
87. Jackisch C, Louwen F, Schwenkhausen A, et al. Lung cancer during pregnancy involving the products of conception and a review of the literature. *Arch Gynecol Obstet.* 2003;268:69–77.
88. Folk JJ, Curioa J, Nosovitch JT Jr, Silverman RK. Poorly differentiated large cell adenocarcinoma of the lung metastatic to the placenta: a case report. *J Reprod Med.* 2004;49:395–397.
89. Alexander A, Samlowski WE, Grossman D, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. *J Clin Oncol.* 2003;21:2179–2186.

90. Alexander A, Harris RM, Grossman D, Bruggers CS, Leachman SA. Vulvar melanoma: diffuse melanosis and metastasis to the placenta. *J Am Acad Dermatol*. 2004;50:293–298.
91. Al-Adnani M, Kiho L, Scheimberg I. Maternal pancreatic carcinoma metastatic to the placenta: a case report and literature review. *Pediatr Dev Pathol*. 2007;10:61–65.
92. Liu J, Guo L. Intraplacentar choriocarcinoma in a term placenta with both maternal and infantile metastases: a case report and review of the literature. *Gynecol Oncol*. 2006;103:1147–1151.
93. Hogg R, Ungar L, Hazslinszky P. Radical hysterectomy for cervical carcinoma in pregnant women—a case of decidua mimicking metastatic carcinoma in pelvic lymph nodes. *Eur J Gynaecol Oncol*. 2005;26:499–500.
94. Dessolle L, Dalmon C, Roche B, Menain N, Darai E. Placental metastases from a maternal squamous cell tumor of the maxillary. *Eur J Obstet Gynecol Reprod Biol*. 2005;123:117–118.
95. Baergen RN, Johnson D, Moore T, Benirschke K. Maternal melanoma metastatic to the placenta: a case report and review of the literature. *Arch Pathol Lab Med*. 1997;121:508–511.
96. Orr JW Jr, Grizzle WE, Huddleston JF. Squamous cell carcinoma metastatic to placenta and ovary. *Obstet Gynecol*. 1982;59:815–835.
97. Potter JF. Metastasis of maternal cancer to placenta and fetus. *Am J Obstet Gynecol*. 1969;105:645.
98. Antaya RJ, Keller RA, Wilkerson JA. Placental nevus cells associated with giant congenital pigmented nevi. *Pediatr Dermatol*. 1995;12:260–262.
99. Jauniaux E, de Meeus MC, Verellen G, Lachapelle JM, Hustin J. Giant congenital melanocytic nevus with placental involvement: long-term follow-up of a case and review of the literature. *Pediatr Pathol*. 1993;13:717–721.
100. Cox JN, Chavrier F. Heterotopic adrenocortical tissue within a placenta. *Placenta*. 1980;1:131–133.
101. Jacques SM, Qureshi F. Adrenocortical and hepatic nodules within placental tissue. *Pediatr Dev Pathol*. 2003;6:464–466.
102. Khaliifa MA, Gersell DJ, Hansen CH, Lage JM. Hepatic (hepatocellular) adenoma of the placenta: a study of four cases. *Int J Gynecol Pathol*. 1998;17:241–244.
103. Bendon RW, Hommel AB. Maternal floor infarction in autoimmune disease: two cases. *Pediatr Pathol Lab Med*. 1996;16:293–297.
104. Adams-Chapman I, Vaucher YE, Bejar RF, Benirschke K, Baergen RN, Moore TR. Maternal floor infarction of the placenta: association with central nervous system injury and adverse neurodevelopmental outcome. *J Perinatol*. 2002;22:236–241.
105. Gersell DJ. Chronic villitis, chronic chorioamnionitis, and maternal floor infarction. *Semin Diagn Pathol*. 1993;10:251–266.
106. Sebire NJ, Backos M, Goldin RD, Regan L. Placental massive perivillous fibrin deposition associated with antiphospholipid antibody syndrome. *BJOG*. 2002;109:570–573.